Alan K. Davis (Johns Hopkins University and later Ohio State University) has been researching the application of psilocybin for depression, anxiety, and loss of meaning for years. His work stands out due to the combination of clinical and qualitative research: he not only measures symptoms but also listens to what participants experience and how they later integrate that experience into their lives.

In a major 2020 study published in JAMA Psychiatry, Davis and colleagues showed that two psilocybin sessions combined with psychotherapy led to a rapid and sustained reduction in depressive symptoms in adults with severe depression. A large proportion of the participants were in remission after four weeks.

A characteristic theme in Davis’ research is meaning-making. Many participants describe a sense of rediscovered meaning, connection, or a new perspective on life after a psilocybin session. This does not appear to be a side effect, but possibly an active factor. For people with PTSD, moral injury, and existential despair, rediscovering meaning is often key to recovery.

Davis emphasizes that psilocybin therapy is not an easy path. The experience itself can be intense and confronting, and subsequent integration requires attention and guidance. However, according to his research, for people for whom other treatments have stalled, it can be a valuable addition to the existing range of care.

Davis advocates for accessible, well-regulated treatment, with attention to the diversity and vulnerability of participants.